July 17, 2020 / 2:18 PM / in a day

FACTBOX-AstraZeneca's potential coronavirus vaccine

    * For FACTBOX on vaccines and treatments, click:

 (Updates with European Union deal, AstraZeneca's 3 billion dose
target)
    Aug 14 (Reuters) - The European Union has agreed to buy at
least 300 million doses of AstraZeneca's potential COVID-19
vaccine, with an option to buy another 100 million.
    Drugmakers are racing to combat the pandemic that has killed
about 760,000 people and infected nearly 21 million.
    There are no approved vaccines for COVID-19, but AstraZeneca's
shot is widely seen as one of the leading candidates.
    The company has been granted protection from future product
liability claims related to the vaccine by most of the countries
with which it has so far struck supply agreements, a senior
executive told Reuters.
    Below are the main details of AstraZeneca's coronavirus vaccine
hopeful and its supply and production deals.
    
    TYPE
    * The shot, called AZD1222 or ChAdOx1 nCoV-19, is a recombinant
viral
vector vaccine developed by Oxford University.
    * It was licensed to AstraZeneca in April.
    * The vaccine candidate uses a weakened version of a chimpanzee
common-cold virus that encodes instructions for making proteins
from the novel coronavirus to build immunity.

    
    PROTECTION DURATION
    * The shot is likely to provide protection for about a year,
and the
company is leaning towards a two-dose strategy for the potential
vaccine.

    
    EXPECTED COST
    * AstraZeneca says it will be able to manufacture the vaccine
at a
few dollars per dose.
    * Pricing in Latin America, while still not final, is not
expected to
exceed $4 per dose, said AstraZeneca's Mexico head.
    * India's Serum Institute said it will price the shot at $3 per
dose
for the country and other emerging economies.
    * According to Italy's health ministry, an AZD1222 shot would
cost
about 2.5 euros ($2.8) per dose in Europe.
    * AstraZeneca has said it does not expect to profit from the
vaccine
candidate during the pandemic.
    * Costs in other regions have not been disclosed.

    
    TRIALS
    * AstraZeneca's CEO said good data has come in so far on the
shot,
after early-stage clinical trials showed it was safe and produced
an immune response. 
    * Late-stage trials are currently underway in Britain, Brazil
and
South Africa, and are due to start in the United States in the
third quarter.
    * Talks are ongoing with Mexico, and reports have said the
Indian
regulator has also given a nod for mid-to-late-stage trials.


    
    TIMELINE    
    * The vaccine could be rolled out by year-end, but there is no
certainty of that, its lead developer said in July.
    * Data from late-stage studies is expected by August to
September.

    * Delivery of the first doses is expected between September and
October.
    * Experts predict a safe and effective vaccine could take 12-18
months to develop.    

    
    TARGET DOSES
    * Recent supply deals take target doses to 3 billion,
AstraZeneca
said.
    

    TIE-UPS 
    * With U.S. backing, AstraZeneca has tied up with IQVIA
to
speed up trials. Even before conclusive evidence of the vaccine's
success or failure, AstraZeneca has signed other deals to produce
and supply the shot. 

    
    MANUFACTURING DEALS  
    
    (Most recent first)     
    
 FIRM          BASED IN  DEAL VALUE   FOR            FURTHER
 Foundation    Mexico    Unknown      Latin          [nL1N2FF
 of Mexican                           American       01U]
 billionaire                          supply with    
 Carlos Slim                          Argentina,     
                                      excluding      
                                      Brazil         
 mAbxience of  Argentin  Unknown      Initially      [nL1N2FF
 the INSUD     a                      producing 150  01U]
 Group                                million doses  
                                      for Latin      
                                      America,       
                                      excluding      
                                      Brazil         
 Kangtai Bio   China     Unknown      Annual         [nL4N2F8
                                      production     2GT]
                                      capacity of    
                                      at least 100   
                                      million doses  
                                      this year,     
                                      and  at least  
                                      200 million    
                                      doses by the   
                                      end of next    
                                      year           
 Emergent      U.S.      $174         Undisclosed    [nL3N2EY
 BioSolutions            million      doses          2LF]
                                                     
 SK            South     Unknown      Undiluted      [nL3N2ES
 Bioscience    Korea                  solutions of   288]
                                      the vaccine    
 R-Pharm       Russia    Unknown      Unknown doses  [nL5N2EO
                                                     2S4]
 Daiichi       Japan     Unknown      Unknown doses  [nL4N2E3
 Sankyo                                              19J]
                                                     
 Fundação      Brazil    $127         About 30       [nL1N2E4
 Osvaldo Cruz            million      million doses  03I]
 (Fiocruz)                                           
 Symbiosis     Scotland  Undisclosed  Clinical       [nL4N2E1
 Pharmaceutic                         trial supply   2U2]
 al                                                  
 Cobra         U.S.      Undisclosed  One million    [nL8N2DT
 Biosciences                          doses per      1YB]
                                      month          
 Catalent      U.S.      Undisclosed  Vial filling   [nL4N2DS
                                      and packaging  2XW]
 Emergent      U.S.      $87 million  300 million    [nL4N2DO
 BioSolutions                         doses          2U1]
                                                     
 Serum         India     Undisclosed  One billion    [nL4N2DH
 Institute of                         doses for low  3LY]
 India                                and            
                                      middle-income  
                                      countries,     
                                      with 400       
                                      million        
                                      before end of  
                                      2020           
 Oxford        UK        Undisclosed  Undisclosed    [nL4N2DL
 Biomedica                            doses          1B3]
                                                     
 
    
               
    SUPPLY DEALS
    
    (Most recent first)
    
 REGION/FIRM      DOSES         FUNDING     DELIVERIES     FURTHER
 European Union   300 million,  Undisclose  By end of      [nL8N2FG
                  with option   d           2020           2XV]
                  of                                       
                  additional                               
                  100 million                              
 Latin America,   Initially     Estimated   First half of  [nL1N2FF
 excluding        produce 150   at $600     2021           01U]
 Brazil           million       million                    
                  doses, and    for the                    
                  eventually    first 150                  
                  make at       million                    
                  least 400     doses                      
                  million                                  
 Japan            120 million   Undisclose  30 million     [nL4N2F9
                  doses         d           doses by       2XN]
                                            March 2021     
 China            Annual        Unknown     By end of      [nL4N2F8
                  production                2020           2GT]
                  capacity of                              
                  at least 100                             
                  million                                  
                  doses this                               
                  year                                     
 South Korea      Unknown       Unknown     Unknown        [nL3N2ES
                                                           288]
 Russia           Unknown       Unknown     Unknown        [nL5N2EO
                                                           2S4]
 Israel           Unknown       Unknown     Unknown        [nL5N2ER
                                                           4TW]
 Brazil           Initially     $356        Unknown        [nL1N2F8
                  receive 100   million                    2TN]
                  million                                  
                  doses                                    
 France,          300 million,  750         By end of      [nL8N2DQ
 Germany, Italy   with option   million     2020           0GG]
 and the          of            euros for                  
 Netherlands      additional    300                        
 under Inclusive  100 million   million                    
 Vaccines                       doses                      
 Alliance (IVA)                                            
 Italy (part of   75 million    185         By end of      [nL8N2DS
 IVA)                           million     2020           2XO]
                                euros                      
 Serum Institute  One billion,  Unknown     400 million    [nL4N2DH
 of India         unspecified               before the     3LY]
                  number of                 end of 2020    
                  doses will                               
                  go to India                              
 Epidemic         300 million   $750        Some before    [nFWN2DH
 response group                 million,    end of 2020    0DK]
 CEPI and                       with $383                  
 Vaccine                        from CEPI                  
 alliance GAVI                                             
 United States    300 million   $1.2        By Oct         [nL4N2D3
                                billion                    1M3]
 United Kingdom   100 million   Unknown     By Sept/Oct    [nRSU597
                                                           2Na]
 
    
    AstraZeneca is also in talks with Spain. 

    
    Sources: Reuters reporting, press releases
    
    
    ($1 = 0.8850 euros)
    ($1 = 0.8156 pounds)

    
 (Reporting by Pushkala Aripaka in Bengaluru; Additional reporting
by Tanishaa Nadkar; Editing by Jason Neely, Nick Macfie, Sherry
Jacob-Phillips and Jan Harvey)
  
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below